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Evaluation of the combined effect of IL28B and PNPLA3 geno-
types on treatment outcomes may permit to discriminate
whether steatosis has indeed a causal role in determining resis-
tance to antivirals, or the association is an epiphenomenon due
to the confounding association of steatosis with IL28B
rs12979860 CC, as suggested by Tillmann et al. [4].
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Table 1. Independent predictors of steatosis in 567 non genotype-3 CHC
patients.
OR 95% CI p
Age (yr) 1.04 1.02-1.05 <0.0001
BMI (kg/m2) 1.20 1.13-1.28 <0.0001
PNPLA3 rs738409 GG 3.36 1.50-8.70 0.0025
IL28B rs12979860 CC 0.57 0.38-0.85 0.0060
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1210Reply to: ‘‘Interaction between IL28B and PNPLA3 genotypes
in the pathogenesis of steatosis in chronic hepatitis C
non genotype-3 patients’’Editor:
nk Dr. Valenti et al. for raising an additional point that
might be associated with steatosis in the setting of HCV
n after controlling for IL28B [1]. They demonstrate in their
of 567 treatment naïve patients that both IL28B
9860) and PNPLA3 (rs738409) may contribute to steato-
rthermore, in their study the beneﬁcial effect of IL28B
ited to the patients without the PNPLA3 risk allele ‘‘G’’
8409. A role of PNPLA3 GG genotype for steatosis in HCV
d patients has been observed in several studies, especially
xcluding genotype 3 patients [2–5]. In the Duke cohort,
not ﬁnd a signiﬁcant difference for steatosis in relation
to PNPLA3, (25/52 vs. 67/127, p = 0.623). However, in the European
cohort, the rs738409 SNP was used instead of SNP rs2281135.
The SNP rs2281135 is considered a tagging SNP (rs2281135) for
the likely causal SNP (rs738409) within the PNPLA3 region. Thus,
as we had a tagging SNP (rs2281135) for the likely causal SNP
(rs738409) within the PNPLA3 region only for the Duke cohort,
we cannot rule out that the lack of a signiﬁcant difference is
due to the lack of accuracy of a surrogate SNP. Interestingly
though, when grouped according to PNPLA3 rs2281135 GG vs.
non-GG, the role of IL28B remained signiﬁcant in the PNPLA3
rs2281135 GG patients only (p = 0.002), while it was only a trend
in the non-GG patients (p = 0.46).
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An association of IL28B and steatosis was also found in several
other [1,2,5,6] but not all studies. A study by Trépo et al., evaluat-
ing both PNPLA3 (rs738409) and IL28B (rs12979860), reported no
association between steatosis and rs12979860 but for rs738409.
Thus, a trend could not be excluded. The data for rs12979860
were not given in the original paper but are included now in
Table 1. These data are actually in line with the other published
data, in that way that there is a trend for IL28B CC genotype being
associated with absence of steatosis, though not signiﬁcantly
(p = 0.12).
Of note, the IL28B CC genotype’s impact seems to concern
mainly patients without the ‘‘at risk’’ PNPLA3 GG genotype, thus
conﬁrming Dr. Valenti et al. observation. Trépo et al. also evalu-
ated multiple tagging SNPs within the PNPLA3 region including
rs2281135, which revealed a p value of 0.017 compared to the
p value of 0.009 for rs738409 for steatosis >5%. These two SNPs,
rs738409 and rs2281135, are partially correlated (i.e. in linkage
disequilibrium) [7].
Thus, overall, the data indicate the PNPLA3 and IL28B have
somewhat independent effects on steatosis. Furthermore, the
study highlights that tagging SNPs are likely to be not accurate
enough. To illustrate further, whereas we found steatosis associ-
ated with IL28B rs12979860 (the most strongly associated SNP
for HCV clearance in Caucasians [6]), we did not ﬁnd a similar sig-
niﬁcant association of steatosis with IL28B rs8880917, which is in
linkage disequilibrium with rs12979860 and may be a poorer
marker of treatment response. In summary, this data might high-
light the importance of choosing the right SNP in situations
where several tagging SNPs can be used.
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Table 1. Frequency of steatosis. (A) PNPLA3 grouping within IL28B groups in the Duke and European cohort respectively. (B) IL28B grouping within PNPLA3 groups in the
Duke and European cohort respectively.
Duke cohort IL28B rs12979860 PNPLA3 rs2281135 No steatosis (%) Steatosis (%) p
“non-CC”* AA or AG 12/28 (42.9) 16/28 (57.1) 0.433
GG 19/60 (31.7) 41/60 (68.3)
“CC” AA or AG 6/10 (60) 4/10 (40) 0.957
GG 21/32 (65.5) 11/32 (34.4)
European cohort IL28B rs12979860 PNPLA3 rs738409 No steatosis (%) Steatosis (%) p
“non-CC”** CC or CG 66/195 (33.8) 129/195 (66.2) 0.101 
GG 2/17 (11.8) 15/17 (88.2)
“CC” CC or CG 31/63 (49.2) 32/69 (50.8) 0.009
GG 1/12 (8.3) 11/12 (91.7)
Duke cohort PNPLA3 rs2281135 IL28B rs12979860 No steatosis (%) Steatosis (%) p
AA or AG “non-CC” 12/28 (42.9) 16/28 (57.1) 0.468
“CC” 6/10 (60) 4/10 (40)
GG “non-CC” 19/60 (31.7) 41/60 (68.3) 0.002
“CC” 21/32 (65.5) 11/32 (34.4)
European cohort PNPLA3 rs738409 IL28B rs12979860 No steatosis (%) Steatosis (%) p
CC or CG  “non-CC” 66/195 (33.8) 129/195 (66.2) 0.036
“CC” 31/63 (49.2) 32/69 (50.8)
GG  “non-CC” 2/17 (11.8) 15/17 (88.2) 1.00
“CC” 1/12 (8.3) 11/12 (91.7)
A
B
In (A), ⁄CC vs. non-CC signiﬁcant at p = 0.002 in the Duke cohort; ⁄⁄CC vs. non-CC not signiﬁcant at p = 0.12 in the European cohort.
PNPLA3 rs2281135 shows only small trend for association with steatosis in the Duke cohort in either IL28B group. Interestingly, in the European cohort this trend was not
signiﬁcant in the ‘‘non-CC’’ group, but reached signiﬁcance in the IL28B ‘‘CC’’ groups.
In (B), ⁄AA or AG vs. GG are not signiﬁcant at p = 0.62 in the Duke cohort; ⁄⁄CC or CG vs. GG are signiﬁcant at p = 0.003 in the European cohort.
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The quest for the elusive factors that underpin
neutrophil dysfunction in cirrhosis goes on
To the Editor:
We congratulate Tritto and colleagues on their recently published
study [1], which aimed at extending our understanding of why
patients with cirrhosis paradoxically exhibit features of impaired
bacteriocidal capacity despite maintaining the ability to generate
inﬂammation and bystander tissue damage. The neutrophil is a
key component of the innate immune system and has been
shown to play a vital role in the development of systemic inﬂam-
mation and organ failure in sepsis [2]. The evidence base support-
ing neutrophil malfunction in acute and chronic liver disease
continues to grow although factors that underpin this dysfunc-
tion are less clear and are likely to be related to a number of
different factors [3–6].
In their study, Tritto and colleagues explore how the exposure
of normal neutrophils to plasma from patients with varying
severity and aetiology of liver disease in vitromay impact on their
function. Furthermore, they aimed at investigating what role the
presence of bacterial DNA, endotoxin and circulating cytokines
within that plasma might play on neutrophil function and Toll-
like receptor (TLR) expression. Lastly, they used a novel aseptic
inﬂammation technique (blister study) to assess how neutrophils
behave in vivo in 8 patients with Child Pugh A/B alcohol-related
cirrhosis. The resulting data are both important and insightful
but we would urge that these data need to be interpreted with
caution at this stage due to several inherent ﬂaws that exist in
the study methodology.
Firstly, further clariﬁcation on the control data is warranted.
In the in vitro part of the study, the authors state that age- and
sex-matched healthy volunteers were used as normal controls.
No further details are given as to the control demographics or
number of controls used, which appear to vary signiﬁcantly in
number between several ﬁgures in the manuscript. This is critical
as the range of phagocytic capacity found in the healthy controls
is vast (50,000–225,000 geometric mean of ﬂuorescence intensity
[GMFI]), suggesting the neutrophil function within the control
group was highly variable and making valid statistical compari-
sons hard to achieve. A number of factors can inﬂuence neutro-
phil function in ‘healthy’ individuals including ethnicity,
alcohol, tobacco habits and exercise within the previous 24 h
which need to be controlled for. This is also fundamental when
interpreting the blister studies, as 3 out of the 5 healthy controls
had reduced phagocytic capacity of a similar magnitude to the
cirrhotic patients and 2 patients stayed the same. This is some-
what at odds with the conclusion that the cirrhotic patients have
impaired neutrophil phagocytic capacity in the blister ﬂuid com-
pared to controls. Moreover, there was a huge variation in GMFI
in the cirrhotic patients (range 25,000–225,000). Four of the eight
patients with cirrhosis also had evidence of impaired phagocytic
capacity in peripheral blood at baseline, clouding the argument
that stable cirrhotic patients did not have impairment of
phagocytic capacity in peripheral blood but did in the inﬂamma-
tory environment.
Secondly, with regard to the TLR data, the baseline expression
of TLR-2, 4 and 9 is not stated prior to exposure to cirrhotic
plasma. This makes it difﬁcult to interpret the impact of the cir-
rhotic plasma on the normal neutrophils. It might also have been
better to have used healthy control plasma rather than phos-
phate-buffered saline which might have signiﬁcantly inﬂuenced
the neutrophil viability and the rate of apoptosis. It would also
be interesting to determine whether the presence or absence of
ascites had any relationship with baseline TLR-4 expression,
which might be expected if this cohort has an increased rate of
gut bacterial translocation.
Lastly, we would be keen to learn more about the cohort
(n = 34) with high oxidative burst. Did a large proportion of these
patients have alcohol-related disease, ascites or encephalopathy?
It is also fascinating to see that these patients had increased lev-
els of IL-12, IFN-gamma and TNF-alpha. IL-12 and IFN-gamma are
not cytokines that are typically associated with neutrophil activa-
tion and may have been released by other immune cell subtypes
such as dendritic cells, macrophages and natural killer cells,
which will undoubtedly have a role to play.
In an ongoing prospective longitudinal cohort study of neu-
trophil morphology, phenotype and function at King’s College
Hospital in over 125 patients with cirrhosis, we have shown
that phagocytic dysfunction is universal in patients with cir-
rhosis (including those with Child Pugh A disease), which is
reversible following liver transplantation [7]. Neutrophil dys-
function is likely to be determined by a large number of vari-
ables including plasma complement, immunoglobulin, sodium
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